These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 8578503

  • 1. Activated protein C resistance: molecular mechanisms.
    Griffin JH, Heeb MJ, Kojima Y, Fernández JA, Kojima K, Hackeng TM, Greengard JS.
    Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
    [Abstract] [Full Text] [Related]

  • 2. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
    Heeb MJ, Kojima Y, Greengard JS, Griffin JH.
    Blood; 1995 Jun 15; 85(12):3405-11. PubMed ID: 7780127
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
    Dahlbäck B.
    Thromb Haemost; 1995 Jul 15; 74(1):139-48. PubMed ID: 8578447
    [Abstract] [Full Text] [Related]

  • 5. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V, Leone G.
    Haematologica; 1995 Jul 15; 80(4):344-56. PubMed ID: 7590506
    [Abstract] [Full Text] [Related]

  • 6. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G, Nicolaes GA, Rosing J.
    Semin Hematol; 1997 Jul 15; 34(3):244-55. PubMed ID: 9241709
    [Abstract] [Full Text] [Related]

  • 7. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter C.
    Thromb Haemost; 1996 Feb 15; 75(2):229-32. PubMed ID: 8815565
    [Abstract] [Full Text] [Related]

  • 8. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB, Sturk A.
    Eur J Clin Chem Clin Biochem; 1997 Jul 15; 35(7):501-16. PubMed ID: 9263726
    [Abstract] [Full Text] [Related]

  • 9. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
    Aparicio C, Dahlbäck B.
    Biochem J; 1996 Jan 15; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
    [Abstract] [Full Text] [Related]

  • 10. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF, Lensen RP, Bertina RM.
    Thromb Haemost; 1997 Feb 15; 77(2):252-7. PubMed ID: 9157576
    [Abstract] [Full Text] [Related]

  • 11. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
    Zöller B, Holm J, Svensson P, Dahlbäck B.
    Thromb Haemost; 1996 Feb 15; 75(2):270-4. PubMed ID: 8815575
    [Abstract] [Full Text] [Related]

  • 12. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
    Heeb MJ, Rehemtulla A, Moussalli M, Kojima Y, Kaufman RJ.
    Eur J Biochem; 1999 Feb 15; 260(1):64-75. PubMed ID: 10091585
    [Abstract] [Full Text] [Related]

  • 13. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
    Pereira J, Quiroga T, Goycoolea M, Muñoz B, Hidalgo P, Kaltwasser G, Mezzano D.
    Rev Med Chil; 1996 Jun 15; 124(6):663-8. PubMed ID: 9041721
    [Abstract] [Full Text] [Related]

  • 14. Mutation in blood coagulation factor V associated with resistance to activated protein C.
    Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH.
    Nature; 1994 May 05; 369(6475):64-7. PubMed ID: 8164741
    [Abstract] [Full Text] [Related]

  • 15. Early days of APC resistance and FV Leiden.
    Dahlbäck B.
    Hamostaseologie; 2008 May 05; 28(3):103-9. PubMed ID: 18521487
    [Abstract] [Full Text] [Related]

  • 16. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease.
    Zöller B, He X, Dahlbäck B.
    Thromb Haemost; 1995 May 05; 73(5):743-5. PubMed ID: 7482396
    [Abstract] [Full Text] [Related]

  • 17. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.
    Villoutreix BO, Dahlbäck B.
    Protein Sci; 1998 Jun 05; 7(6):1317-25. PubMed ID: 9655335
    [Abstract] [Full Text] [Related]

  • 18. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons.
    Dahlbäck B.
    Thromb Haemost; 1995 May 05; 73(5):739-42. PubMed ID: 7482395
    [No Abstract] [Full Text] [Related]

  • 19. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
    Zöller B, Svensson PJ, He X, Dahlbäck B.
    J Clin Invest; 1994 Dec 05; 94(6):2521-4. PubMed ID: 7989612
    [Abstract] [Full Text] [Related]

  • 20. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
    Dahlbäck B.
    Semin Hematol; 1997 Jul 05; 34(3):217-34. PubMed ID: 9241707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.